Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Azizur Rahman
 -- 2087 2022-06-28 08:05:05 |
2 layout
Jessie Wu
 Meta information modification 2087 2022-06-29 02:46:10 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Rahman, A. Marine Resources for the Omicron SARS-CoV-2 Variant. Encyclopedia. Available online: https://encyclopedia.pub/entry/24547 (accessed on 26 December 2024).
Rahman A. Marine Resources for the Omicron SARS-CoV-2 Variant. Encyclopedia. Available at: https://encyclopedia.pub/entry/24547. Accessed December 26, 2024.
Rahman, Azizur. "Marine Resources for the Omicron SARS-CoV-2 Variant" Encyclopedia, https://encyclopedia.pub/entry/24547 (accessed December 26, 2024).
Rahman, A. (2022, June 28). Marine Resources for the Omicron SARS-CoV-2 Variant. In Encyclopedia. https://encyclopedia.pub/entry/24547
Rahman, Azizur. "Marine Resources for the Omicron SARS-CoV-2 Variant." Encyclopedia. Web. 28 June, 2022.
Marine Resources for the Omicron SARS-CoV-2 Variant
Edit
This entry is adapted from the peer-reviewed paper 10.3390/covid2040037

In November of 2021, a recently evolved variant of SARS-CoV-2, omicron, was discovered. In just one month, omicron has spread to more than 89 countries resulting in a rapid rise in cases and a new wave of infections. With over 46 mutations, omicron brings concern to the public health and may be able to infect at a greater capacity than previous strains. Although able to infect double vaccinated and previously infected individuals, the booster vaccine may prove promising. However, more research is needed to fully elucidate the key function of each mutation and to better develop effective drugs. Marine resources may be a promising drug discovery avenue to investigate. Through viral entry blockade and preventing viral replication and protein synthesis, metabolites produced from marine organisms may be promising against the evolving SARS-CoV-2.

omicron marine resources COVID-19

1. Introduction

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first emerged almost two years ago and has been ongoing since [1]. It is without a doubt that the SARS-CoV-2 pandemic has led to frustration and prevalent negative effects on the mental wellbeing of individuals as well as the economy [2][3][4]. Vaccinations were effective at first, however, the solution was temporary, and the single-stranded SARS-CoV-2 virus is continuously evolving through mutations in key domains [5][6][7][8]. Several SARS-CoV-2 variants including the alpha, beta and delta strains were associated with new waves of COVID-19 infection [9][10]. The delta variant was shown to have a higher transmissible and infectious risk than other strains with reports of having a higher viral load and mutations granting a better immune response escape [11][12][13].
On 24 November 2021, a new SARS-CoV-2 variant, known as omicron (B.1.1.529) was reported to World Health Organization (WHO) [14]. The omicron variant was first reported on 11 November 2021, in Botswana and just a few days later, was identified in South Africa [15][16]. To date (January 2022), omicron has been reported in more than 57 countries, with South Korea reporting its highest number of COVID-19 cases in December 2021, since the start of the pandemic [17]. It has not been elucidated whether the transmissibility and severity status of the omicron variant is greater than the previous strains [18][19]. Over 45 mutations and several gene deletions have been identified, some in the same genes as the previous variants and others being novel (Figure 1) [20]. Together, these mutations in key regions give the omicron strain the ability to escape the host immune system, rendering vaccinations less effective [20][21]. Furthermore, it is not clear yet what the effects of several mutations are, and this serves as a barrier for developing new vaccinations or drugs for prevention and treatment of omicron viral infection [22][23].
Covid 02 00037 g001 550
Figure 1. A comparison of few key missense mutations in the spike protein of previous SARS-CoV-2 variants and the omicron variant. As seen in the image on the left, previous variants (i.e., delta variant) had few mutations that favored viral infection. Seen on the right, omicron has more mutations, many of which function to increase binding affinity to host ACE-2 receptor and potentially increase infectivity ability as well as transmissibility of viral particles. Some mutations such as T478K overlap with previous variants, and some (i.e., E484A) are unique to omicron. (Created with BioRender.com (accessed on 19 December 2021)).
Previous variants have shown to lower the efficacy of vaccinations. For example, the efficacy of the AstraZeneca ChAdOx1 vaccine decreased to 10% in South Africa because of the beta SARS-CoV-2 variant [19]. The re-purposing of drugs used for anti-bacterial infections or other anti-viral infections may be a promising avenue to investigate. Marine resources have a variety of molecules that have shown to have anti-viral abilities and their repurposing for treatment against omicron may be promising [24][25][26]. Specifically, inorganic polyphosphate has been shown to inhibit viral life cycle at several stages by blocking viral particle spike protein binding to host ACE-2 receptor and inhibiting viral protein synthesis once inside the cell [26][27]. Similarly, lambda-carrageenan isolated from marine algae have also been shown to inhibit viral protein transcription and translation [28]. Moreover, bromotyrosines have also been shown to have anti-bacterial and anti-viral activity, and have recently been isolated and purified for further research [24][29]. Although some challenges are ahead such as large-scale production and more in vivo studies necessary for further development, more research is warranted to determine the full potential of marine metabolites against SARS-CoV-2 variants.

2. The Potential for Prevention/Treatment of SARS-CoV-2 Variants Using Marine Resources

Considering the rapid rise in cases as well as the continuously evolving SARS-CoV-2 virus, there needs to be more effective vaccinations and drugs to prevent and treat not only the omicron variant but other future variants as well. One such drug discovery avenue to investigate is marine resources [30][31][32]. Marine resources harbor significant activity against cancer, viruses and bacteria, thus their ability to prevent or treat omicron viral infection should be investigated [29][33][34][35][36]. In fact, marine resources, which can be isolated from invertebrates and cultivated under farming conditions (i.e., sponges) [37][38], are highly advantageous over synthetic compounds as they lack religious constraints, have little to no toxins, are environmentally friendly and are metabolically compatible [24]. Furthermore, marine compounds isolated from a single organism can often combat several stages of the viral life cycle, including both viral entry and replication [39] (Figure 2).
Covid 02 00037 g004 550
Figure 2. Overview of marine compounds interfering with the SARS-CoV-2 viral life cycle. Image depicts several marine substances that can inhibit various steps of the life cycle which may be relevant to treatment. (Created with BioRender.com (accessed on 25 March 2022)).
Inorganic polyphosphate (polyP) are abundantly found in marine bacteria and sponges and have been shown to bind RBD of SARS-CoV-2 and prevent ACE-2 binding [27]. Several phosphate units of polyP are thought to interact with the spike protein through basic residues like Arginine, Lysine and Histidine [26][27]. Neuforth et al. found that polyP was able to inhibit the spike protein and ACE-2 interaction dose-dependently (up to 100 μg/mL) [26]. This inhibition was found to be 70% effective and during the 24 h incubation period, 100 μg/mL of polyP had no toxic effect on the cells. In addition, polyP is versatile in that it has also been shown to stimulate the innate antiviral immune system, by upregulating the mucin gene, MUC1 [26][27][36]. By boosting the innate immune response, polyP may serve a protective role as immunity plays an important role in the onset of COVID-19 symptoms and infection in patients. To add, Ferrucci et al. found that a long chain polyP is able to impair replication and transcription of viral particles, and this prevents the synthesis of viral proteins [26]. The study also found that polyP120 is able to bind to and downregulate the ACE-2 receptor by resulting in its degradation. It is clear that polyP may play a potential role in preventing SARS-CoV-2 infection, however more studies investigating whether polyP interacts with spike protein on conserved or mutated residues is warranted to elucidate its usefulness against the omicron variant. This is important as the omicron variant differs from previous SARS-CoV-2 strains due to mutations in the spike protein, half of which are in the RBD. Thus, targeting stages in the latter portion of the viral life cycle, boosting the innate immune system or targeting the ACE-2 receptor interaction may together serve as competent methods to inhibit viral infection.
Moreover, lambda-carrageenan is a polysaccharide isolated from red algae and has been shown to inhibit influenza virus and SARS-CoV-2 viral replication dose-dependently [24][28]. Studies have found that like polyP, lambda-carrageenan is able to inhibit both viral entry and viral protein synthesis, by blocking transcription and translation of proteins. For example, in a study done by Jang et. al, SARS-CoV-2 viral protein and replication was suppressed dose-dependently in both Influenza A and SARS-CoV-2 viruses after lambda-carrageenan administration [28]. These multi-mechanisms of action likely serve beneficial not only for omicron variant treatment and prevention, but future and more aggressive variants as well. Another molecule of interest that may be redirected for different strains of SARS-CoV-2 viruses includes the pigment compounds phycocyanobilins (PCBs) [40]. In addition to their antioxidant properties, marine PCBs have been shown to inhibit a key conserved enzyme of the virus, main protease (Mpro) [41]. PCBs can also interfere with RNA dependant RNA polymerase (RdRp) of SARS-CoV-2 [40]. These findings are important as they are conserved enzymes among the various viral strains, and the design of drugs that can directly act on these molecules may serve as promising treatments. Similar to the above compounds, sulfated polysaccharides isolated from cyanobacteria and marine algae have been shown to bind to the SARS-CoV-2 viral spike protein and inhibit entry into cells [42]. One sulfated polysaccharide, iota-carrageenan, has been previously demonstrated to be effective against several respiratory virsuses, in vitro [43]. A recent study by Morokutti-Kurz et al. found that this molecule was able to inhibit the entry of a SARS-CoV-2 psudeotyped lentivirus dose-dependently with an IC50 of 2.6 µg/mL [44]. This is thought to be occurring through formation of a sulfated polysaccharide-ACE-2 complex which prevents the binding of the spike protein, and through the anionic sulfate groups interacting with the spike protein residues preventing ACE-2 interaction and thus, viral entry [44].
To add, marine sponges have been shown to rapidly filter out viruses and have highly specialized defense mechanisms against viral particles. One promising compound, bromotyrosine, is produced by the marine demosponges of Verongiida order in specialized spherulocyte cells and has been shown to have promising anti-viral effects [29][45][46][47]. These cells are sensitive to environmental stimuli and release bromotyrosine in response to damage. Muzychka et al. have recently isolated and purified a bromotyrosine derivative, 3,5-dibromoquinolacetic acid and found to have anti-bacterial capabilities [29]. Bromotyrosines have been shown to also have antiviral activity against HIV-1 retrovirus by inhibiting its entry into host cells as well as its replication inside the cell. Bromotyrosines are promising compounds to investigate for SARS-CoV-2 infection blockade. More research is needed to understand if bromotyrosines can target conserved residues on the spike protein, and whether they can inhibit viral proliferation once inside the host cell. Both bacterial and COVID-like viruses contain a lipid wall and cell adhesive proteins on their surface. While current drug development aims at targeting their surface proteins, their constant mutation significantly limits drug efficacy. The lipid wall or capsule is conserved in structure and does not mutate as frequently; this makes it a promising drug target. Researchers suggest that bromotyrosines act through lipid surface of both bacterial and viruses protecting the sponges from such pathogens [29]. If so, bromotyrosines should be effective against any kind of viruses, including omicron.
Promisingly, a recent study by Bharathi et al. identified natural bioactive compounds isolated from various marine seaweed species, as inhibitors of the omicron variant [48]. Molecular docking analysis showed that two compounds, caffeic acid hexoside and phloretin isolated from Sargassum wightii were able to inhibit important residues necessary for ACE-2 interaction (ASN417, SER496, TYR501, and HIS505) [48]. This is significant as these 4 residues in the RBD of the omicron spike protein were found to most strongly bind ACE2 receptor. Phloretin has also been shown to activate transcription factors that can upregulate the expression of antioxidant enzymes like superoxide dismutase and glutathione peroxidase [49]. These enzymes play an important role in reducing oxidative stress and inflammation in SARS-CoV-2 infected patients suggesting it has promising effects. Furthermore, several other compounds including cholestan-3-ol and 2-methylene from the Corallina officinalis were able to inhibit the novel mutated residues, LEU452 and ALA484 on the RBD of the spike protein [48]. This inhibition was found to be through hydrogen bonding and alkyl interactions. All together, it is clear that several seaweed compounds as well as compounds isolated from other marine organisms may be effective against omicron infection, however future experimental studies are warranted to support these findings (Table 1).
Table 1. Summary of marine compounds and their mechanisms of action for potential omicron treatment.
Marine Compound Sources Mechanism of Action
Inorganic polyphosphate (polyP) [26][27] Marine bacteria and sponges
-
Interacts with spike proteins by binding basic residues (Arg, Lys, His)
-
Binds RBD of spike protein and interferes with ACE-2 interaction
-
PolyP120 downregulates ACE-2 receptor by stimulating its degradation
-
Upregulates mucin genes and stimulates the innate immune system
-
Impairs viral transcription and replication
Lambda-carrageenan [24][28] Marine algae
-
Interferes with viral entry into the cell
-
Inhibits viral protein synthesis by interfering with transcription and translation
Phycocyanobilins (PCB) [40][41] Cyanobacteria and algae rhodophytes
-
Inhibits conserved enzymes Mpro and RdRp
Sulfated polysaccharides [42][43][44] Cyanobacteria, sea cucumber, microalgae
-
Forms complex with ACE-2 receptor and binds viral spike protein
-
Anionic properties allow for shielding against virus
Bromotyrosines [29][46][47][50] Marine sponges
-
Inhibits viral entry, replication and protein synthesis of HIV-1
-
Blocks SARS-CoV-2 viral entry by inhibiting ACE-2 interaction
Caffeic acid hexoside, phloretin, cholestan-3-ol, 2-methylene [48][49] Marine seaweed
-
Inhibit mutated residues on RBD of omicron spike protein and prevent ACE-2 interaction
-
Phloretin upregulates antioxidant enzymes by activating transcription factors

References

  1. Yang, L.; Liu, S.; Liu, J.; Zhang, Z.; Wan, X.; Huang, B.; Chen, Y.; Zhang, Y. COVID-19: Immunopathogenesis and Immunotherapeutics. Sig. Transduct. Target. Ther. 2020, 5, 128.
  2. Talevi, D.; Socci, V.; Carai, M.; Carnaghi, G.; Faleri, S.; Trebbi, E.; di Bernardo, A.; Capelli, F.; Pacitti, F. Mental Health Outcomes of the COVID-19 Pandemic. Riv. Psichiatr. 2020, 55, 137–144.
  3. Jin, H.; Wang, H.; Li, X.; Zheng, W.; Ye, S.; Zhang, S.; Zhou, J.; Pennington, M. Economic Burden of COVID-19, China, January–March, 2020: A Cost-of-Illness Study. Bull. World Health Organ. 2021, 99, 112–124.
  4. Oberndorfer, M.; Dorner, T.E.; Brunnmayr, M.; Berger, K.; Dugandzic, B.; Bach, M. Health-related and Socio-economic Burden of the COVID-19 Pandemic in Vienna. Health Soc. Care Commun. 2021.
  5. Rahman, M.S.; Islam, M.R.; Alam, A.S.M.R.U.; Islam, I.; Hoque, M.N.; Akter, S.; Rahaman, M.M.; Sultana, M.; Hossain, M.A. Evolutionary Dynamics of SARS-CoV-2 Nucleocapsid Protein and Its Consequences. J. Med. Virol. 2021, 93, 2177–2195.
  6. Giovanetti, M.; Benedetti, F.; Campisi, G.; Ciccozzi, A.; Fabris, S.; Ceccarelli, G.; Tambone, V.; Caruso, A.; Angeletti, S.; Zella, D.; et al. Evolution Patterns of SARS-CoV-2: Snapshot on Its Genome Variants. Biochem. Biophys. Res. Commun. 2021, 538, 88–91.
  7. Shah, M.; Woo, H.G. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escape Approved COVID-19 Therapeutic Antibodies. Genomics 2021.
  8. Spratt, A.N.; Kannan, S.R.; Woods, L.T.; Weisman, G.A.; Quinn, T.P.; Lorson, C.L.; Sönnerborg, A.; Byrareddy, S.N.; Singh, K. Evolution, Correlation, Structural Impact and Dynamics of Emerging SARS-CoV-2 Variants. Comput. Struct. Biotechnol. J. 2021, 19, 3799–3809.
  9. Duong, D. Alpha, Beta, Delta, Gamma: What’s Important to Know about SARS-CoV-2 Variants of Concern? CMAJ 2021, 193, E1059–E1060.
  10. Cele, S.; Karim, F.; Lustig, G.; San, J.E.; Hermanus, T.; Tegally, H.; Snyman, J.; Moyo-Gwete, T.; Wilkinson, E.; Bernstein, M.; et al. SARS-CoV-2 Evolved during Advanced HIV Disease Immunosuppression Has Beta-like Escape of Vaccine and Delta Infection Elicited Immunity. Infect. Dis. 2021.
  11. Wang, Y.; Chen, R.; Hu, F.; Lan, Y.; Yang, Z.; Zhan, C.; Shi, J.; Deng, X.; Jiang, M.; Zhong, S.; et al. Transmission, Viral Kinetics and Clinical Characteristics of the Emergent SARS-CoV-2 Delta VOC in Guangzhou, China. EClinicalMedicine 2021, 40, 101129.
  12. van Kampen, J.J.A.; van de Vijver, D.A.M.C.; Fraaij, P.L.A.; Haagmans, B.L.; Lamers, M.M.; Okba, N.; van den Akker, J.P.C.; Endeman, H.; Gommers, D.A.M.P.J.; Cornelissen, J.J.; et al. Duration and Key Determinants of Infectious Virus Shedding in Hospitalized Patients with Coronavirus Disease-2019 (COVID-19). Nat. Commun. 2021, 12, 267.
  13. Farinholt, T.; Doddapaneni, H.; Qin, X.; Menon, V.; Meng, Q.; Metcalf, G.; Chao, H.; Gingras, M.-C.; Avadhanula, V.; Farinholt, P.; et al. Transmission Event of SARS-CoV-2 Delta Variant Reveals Multiple Vaccine Breakthrough Infections. BMC Med. 2021, 19, 255.
  14. World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Available online: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern (accessed on 19 December 2021).
  15. Dyer, O. COVID-19: South Africa’s Surge in Cases Deepens Alarm over Omicron Variant. BMJ 2021, 375, n3013.
  16. Wang, L.; Cheng, G. Sequence Analysis of the Emerging SARS-CoV-2 Variant Omicron in South Africa. J. Med. Virol. 2021, 94, 1728–1733.
  17. Mahase, E. COVID-19: Do Vaccines Work against Omicron—and Other Questions Answered. BMJ 2021, 375, n3062.
  18. Ingraham, N.E.; Ingbar, D.H. The Omicron Variant of SARS-CoV-2: Understanding the Known and Living with Unknowns. Clin. Transl. Med. 2021, 11, e685.
  19. Karim, S.S.A.; Karim, Q.A. Omicron SARS-CoV-2 Variant: A New Chapter in the COVID-19 Pandemic. Lancet 2021, 398, 2126–2128.
  20. Kannan, S.R.; Spratt, A.N.; Sharma, K.; Chand, H.S.; Byrareddy, S.N.; Singh, K. Omicron SARS-CoV-2 Variant: Unique Features and Their Impact on Pre-Existing Antibodies. J. Autoimmun. 2022, 126, 102779.
  21. Cao, Y.; Wang, J.; Jian, F.; Xiao, T.; Song, W.; Yisimayi, A.; Huang, W.; Li, Q.; Wang, P.; An, R.; et al. B.1.1.529 Escapes the Majority of SARS-CoV-2 Neutralizing Antibodies of Diverse Epitopes. Immunology 2021.
  22. Kumar, S.; Thambiraja, T.S.; Karuppanan, K.; Subramaniam, G. Omicron and Delta Variant of SARS-CoV-2: A Comparative Computational Study of Spike Protein. J. Med. Virol. 2022, 94, 1641–1649.
  23. Cevik, M.; Grubaugh, N.D.; Iwasaki, A.; Openshaw, P. COVID-19 Vaccines: Keeping Pace with SARS-CoV-2 Variants. Cell 2021, 184, 5077–5081.
  24. Geahchan, S.; Ehrlich, H.; Rahman, M.A. The Anti-Viral Applications of Marine Resources for COVID-19 Treatment: An Overview. Mar. Drugs 2021, 19, 409.
  25. Khan, M.T.; Ali, A.; Wang, Q.; Irfan, M.; Khan, A.; Zeb, M.T.; Zhang, Y.-J.; Chinnasamy, S.; Wei, D.-Q. Marine Natural Compounds as Potents Inhibitors against the Main Protease of SARS-CoV-2—A Molecular Dynamic Study. J. Biomol. Struct. 2021, 39, 3627–3637.
  26. Ferrucci, V.; Kong, D.-Y.; Asadzadeh, F.; Marrone, L.; Boccia, A.; Siciliano, R.; Criscuolo, G.; Anastasio, C.; Quarantelli, F.; Comegna, M.; et al. Long-Chain Polyphosphates Impair SARS-CoV-2 Infection and Replication. Sci. Signal. 2021, 14, eabe5040.
  27. Neufurth, M.; Wang, X.; Tolba, E.; Lieberwirth, I.; Wang, S.; Schröder, H.C.; Müller, W.E.G. The Inorganic Polymer, Polyphosphate, Blocks Binding of SARS-CoV-2 Spike Protein to ACE2 Receptor at Physiological Concentrations. Biochem. Pharmacol. 2020, 182, 114215.
  28. Jang, Y.; Shin, H.; Lee, M.K.; Kwon, O.S.; Shin, J.S.; Kim, Y.; Kim, C.W.; Lee, H.-R.; Kim, M. Antiviral Activity of Lambda-Carrageenan against Influenza Viruses and Severe Acute Respiratory Syndrome Coronavirus 2. Sci. Rep. 2021, 11, 821.
  29. Muzychka, L.; Voronkina, A.; Kovalchuk, V.; Smolii, O.B.; Wysokowski, M.; Petrenko, I.; Youssef, D.T.A.; Ehrlich, I.; Ehrlich, H. Marine Biomimetics: Bromotyrosines Loaded Chitinous Skeleton as Source of Antibacterial Agents. Appl. Phys. A 2021, 127, 15.
  30. Asif, M.; Saleem, M.; Yaseen, H.S.; Yehya, A.H.; Saadullah, M.; Zubair, H.M.; Oon, C.E.; Khaniabadi, P.M.; Khalid, S.H.; Khan, I.U.; et al. Potential Role of Marine Species-Derived Bioactive Agents in the Management of SARS-CoV-2 Infection. Future Microbiol. 2021, 16, 1289–1301.
  31. El-Demerdash, A.; Al-Karmalawy, A.A.; Abdel-Aziz, T.M.; Elhady, S.S.; Darwish, K.M.; Hassan, A.H.E. Investigating the Structure–Activity Relationship of Marine Natural Polyketides as Promising SARS-CoV-2 Main Protease Inhibitors. RSC Adv. 2021, 11, 31339–31363.
  32. Singh, R.; Chauhan, N.; Kuddus, M. Exploring the Therapeutic Potential of Marine-Derived Bioactive Compounds against COVID-19. Environ. Sci. Pollut. Res. 2021, 28, 52798–52809.
  33. Lira, S.P.D.; Seleghim, M.H.R.; Williams, D.E.; Marion, F.; Hamill, P.; Jean, F.; Andersen, R.J.; Hajdu, E.; Berlinck, R.G.S. A SARS-Coronovirus 3CL Protease Inhibitor Isolated from the Marine Sponge Axinella Cf. Corrugata: Structure Elucidation and Synthesis. J. Braz. Chem. Soc. 2007, 18, 440–443.
  34. Drechsel, A.; Helm, J.; Ehrlich, H.; Pantovic, S.; Bornstein, S.R.; Bechmann, N. Anti-Tumor Activity vs. Normal Cell Toxicity: Therapeutic Potential of the Bromotyrosines Aerothionin and Homoaerothionin In Vitro. Mar. Drugs 2020, 18, 236.
  35. Lianingsih, F. In Silico Analysis of Sponges Compound Against Mpro COVID-19: A Review. Proc. Int. Conf. Eng. 2021, 4, 296–300.
  36. Bechmann, N.; Ehrlich, H.; Eisenhofer, G.; Ehrlich, A.; Meschke, S.; Ziegler, C.; Bornstein, S. Anti-Tumorigenic and Anti-Metastatic Activity of the Sponge-Derived Marine Drugs Aeroplysinin-1 and Isofistularin-3 against Pheochromocytoma In Vitro. Mar. Drugs 2018, 16, 172.
  37. Binnewerg, B.; Schubert, M.; Voronkina, A.; Muzychka, L.; Wysokowski, M.; Petrenko, I.; Djurović, M.; Kovalchuk, V.; Tsurkan, M.; Martinovic, R.; et al. Marine Biomaterials: Biomimetic and Pharmacological Potential of Cultivated Aplysina Aerophoba Marine Demosponge. Mater. Sci. Eng. C 2020, 109, 110566.
  38. Ehrlich, H.; Bazhenov, V.; Meschke, S.; Bürger, M.; Ehrlich, A.; Petovic, S.; Durovic, M. Marine Invertebrates of Boka Kotorska Bay Unique Sources for Bioinspired Materials Science. In The Boka Kotorska Bay Environment; Joksimović, A., Djurović, M., Semenov, A.V., Zonn, I.S., Kostianoy, A.G., Eds.; The Handbook of Environmental Chemistry; Springer International Publishing: Cham, Switzerland, 2016; Volume 54, pp. 313–334. ISBN 978-3-319-51613-4.
  39. Hamoda, A.M.; Fayed, B.; Ashmawy, N.S.; El-Shorbagi, A.-N.A.; Hamdy, R.; Soliman, S.S.M. Marine Sponge Is a Promising Natural Source of Anti-SARS-CoV-2 Scaffold. Front. Pharmacol. 2021, 12, 666664.
  40. Pendyala, B.; Patras, A. In Silico Screening of Food Bioactive Compounds to Predict Potential Inhibitors of COVID-19 Main Protease (Mpro) and RNA-Dependent RNA Polymerase (RdRp). Chemistry 2020.
  41. Petit, L.; Vernès, L.; Cadoret, J.-P. Docking and in Silico Toxicity Assessment of Arthrospira Compounds as Potential Antiviral Agents against SARS-CoV-2. J. Appl. Phycol. 2021, 33, 1579–1602.
  42. Song, S.; Peng, H.; Wang, Q.; Liu, Z.; Dong, X.; Wen, C.; Ai, C.; Zhang, Y.; Wang, Z.; Zhu, B. Inhibitory Activities of Marine Sulfated Polysaccharides against SARS-CoV-2. Food Funct. 2020, 11, 7415–7420.
  43. Grassauer, A.; Weinmuellner, R.; Meier, C.; Pretsch, A.; Prieschl-Grassauer, E.; Unger, H. Iota-Carrageenan Is a Potent Inhibitor of Rhinovirus Infection. Virol. J. 2008, 5, 107.
  44. Morokutti-Kurz, M.; Fröba, M.; Graf, P.; Große, M.; Grassauer, A.; Auth, J.; Schubert, U.; Prieschl-Grassauer, E. Iota-Carrageenan Neutralizes SARS-CoV-2 and Inhibits Viral Replication in Vitro. PLoS ONE 2021, 16, e0237480.
  45. Schubert, M.; Binnewerg, B.; Voronkina, A.; Muzychka, L.; Wysokowski, M.; Petrenko, I.; Kovalchuk, V.; Tsurkan, M.; Martinovic, R.; Bechmann, N.; et al. Naturally Prefabricated Marine Biomaterials: Isolation and Applications of Flat Chitinous 3D Scaffolds from Ianthella Labyrinthus (Demospongiae: Verongiida). Int. J. Mol. Sci. 2019, 20, 5105.
  46. Fromont, J.; Żółtowska-Aksamitowska, S.; Galli, R.; Meissner, H.; Erpenbeck, D.; Vacelet, J.; Diaz, C.; Tsurkan, M.V.; Petrenko, I.; Youssef, D.T.A.; et al. New Family and Genus of a Dendrilla-like Sponge with Characters of Verongiida. Part II. Discovery of Chitin in the Skeleton of Ernstilla Lacunosa. Zool. Anz. 2019, 280, 21–29.
  47. Kovalchuk, V.; Voronkina, A.; Binnewerg, B.; Schubert, M.; Muzychka, L.; Wysokowski, M.; Tsurkan, M.V.; Bechmann, N.; Petrenko, I.; Fursov, A.; et al. Naturally Drug-Loaded Chitin: Isolation and Applications. Mar. Drugs 2019, 17, 574.
  48. Bharathi, M.; Sivamaruthi, B.S.; Kesika, P.; Thangaleela, S.; Chaiyasut, C. In Silico Screening of Bioactive Compounds of Representative Seaweeds to Inhibit SARS-CoV-2 ACE2-Bound Omicron B.1.1.529 Spike Protein Trimer. Mar. Drugs 2022, 20, 148.
  49. Behzad, S.; Sureda, A.; Barreca, D.; Nabavi, S.F.; Rastrelli, L.; Nabavi, S.M. Health Effects of Phloretin: From Chemistry to Medicine. Phytochem. Rev. 2017, 16, 527–533.
  50. Schubert, M.; Bertoglio, F.; Steinke, S.; Heine, P.A.; Ynga-Durand, M.A.; Zuo, F.; Du, L.; Korn, J.; Milošević, M.; Wenzel, E.V.; et al. Human Serum from SARS-CoV-2 Vaccinated and COVID-19 Patients Shows Reduced Binding to the RBD of SARS-CoV-2 Omicron Variant. BMC Med. 2022, 20, 102.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Biochemistry & Molecular Biology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Azizur Rahman
View Times: 607
Entry Collection: COVID-19
Revisions: 2 times (View History)
Update Date: 29 Jun 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback